- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00585611
Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients
March 6, 2019 updated by: University of Wisconsin, Madison
The study is designed to define the underlying vascular abnormalities present in patients with diastolic heart failure and test the effect of a therapy aimed at vascular abnormalities.
This study is designed to investigate the effects of therapy with atorvastatin in subjects with diastolic heart failure to improve abnormalities of vascular and myocardial structure and function, with particular emphasis on arterial stiffness and endothelial dysfunction.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Forty subjects will be given either drug (atorvastatin 40 mg) or placebo in a randomized fashion once daily for six months.
Using echocardiography, tonometry, and flow mediated dilation of conduit arteries and arterioles, baseline cardiovascular anatomy and physiology will be defined.
Subjects that enroll in the study will be required to come in for 5 study visits.
The initial visit is a screening visit; subject consent is obtained and an echocardiogram is performed as well as blood tests.
At the randomization visit (4-14 days following screening), the subject will be provided with drug or placebo in a blinded fashion.Also at this visit, subjects will be asked to do a 6 minute walk, QOL questionnaire, and vascular function testing.
There will be follow-up study visits at 1 and 3 months following randomization.
At each follow-up visit a medical history, pill count and brief physical examination will be performed, a repeat QOL questionnaire administered, and blood tests to assess safety of the statin therapy.
At 6 months, the final study visit will occur.
At this visit a full history and detailed physical examination will be performed.
Repeat echocardiogram, 6 minute walk test, QOL questionnaire, and vascular function examinations will be performed.
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Hospital and Clinics
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent,
- Age > 18,
- Ejection fraction ≥ 50%,
- hospitalization for heart failure in the last 6 months and
- current NYHA Class II-IV symptoms, OR
current NYHA Class III-IV symptoms and one of the following:
- ECG or echocardiographic evidence of moderate/severe left ventricular hypertrophy,
- chest x-ray evidence of pulmonary congestion
Exclusion Criteria:
- Probable alternative cause of symptoms (pulmonary disease, severe anemia, etc.)
- Prior documented LVEF < 40% or qualitative moderate or greater LV systolic dysfunction.
- Current indication for statin therapy
- Intolerance to statin therapy.
- Documented ischemic heart disease requiring lipid-lowering therapy (i.e. CAD, myocardial infarction, stroke)
- Evidence of significant myocardial ischemia on stress testing at screening visit.
- Evidence of hepatic abnormality (defined as liver enzymes > 2 times the upper limit of normal values).
- Uncontrolled hypertension (BP > 150/100)
- Significant valvular disease.
- Atrial fibrillation
- Known familial hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy.
- Restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease (i.e. amyloidosis, sarcoidosis, hemochromatosis).
- Cor pulmonale or other cause of right heart failure not related to LV dysfunction.
- Clinically significant pulmonary disease.
- Pericardial constriction or hemodynamically significant pleural effusion.
- Uncontrolled arrhythmia.
- Any systemic condition other than heart failure that may limit survival to less than 2 years.
- Advance renal disease (serum creatinine > 3.0 mg/dl or on dialysis)
- Known intolerance or allergy to HMG CoA reductase inhibitors
- Uncontrolled hyper- or hypothyroidism.
- Any subject characteristic that may interfere with study compliance, such as baseline dementia, substance abuse, history of non-compliance with medications or appointments.
- Prisoners or other vulnerable populations.
- Any woman of child-bearing age with a documented positive pregnancy test.
- Subject is receiving therapy with other investigational therapy or is participating in any other clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
|
placebo
Atorvastatin - 40 mg orally daily for 6 months
|
Experimental: Atorvastatin
Heart failure patients assigned to atorvastatin
|
Atorvastatin - 40 mg orally daily for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Carotid-femoral Pulse Wave Velocity (CFPWV) in the Statin Treated vs. Control Group
Time Frame: 6 months after initiation of intervention
|
6 months after initiation of intervention
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Composite Cardiovascular Endpoint Incorporating Quality of Life (QOL) Assessment + Hospitalizations for Cardiovascular Disease and Mortality
Time Frame: 6 months after initiation of intervention
|
6 months after initiation of intervention
|
Changes in Submaximal Exercise Capacity Measured by 6-minute Walk Test
Time Frame: 6 months after initiation of intervention
|
6 months after initiation of intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nancy K Sweitzer, MD PhD, University of Wisconsin, Madison
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2005
Primary Completion (Actual)
June 1, 2008
Study Completion (Actual)
June 1, 2008
Study Registration Dates
First Submitted
December 26, 2007
First Submitted That Met QC Criteria
January 2, 2008
First Posted (Estimate)
January 3, 2008
Study Record Updates
Last Update Posted (Actual)
March 26, 2019
Last Update Submitted That Met QC Criteria
March 6, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-2005-0430
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diastolic Heart Failure
-
Emory UniversityUnknownDiastolic Heart Failure | Diastolic DysfunctionUnited States
-
CorAssist Cadiovascular Ltd.RecruitingDiastolic Heart Failure | Diastolic DysfunctionIsrael
-
University of VermontCompletedDiastolic Heart Failure | Diastolic Dysfunction | PacemakerUnited States
-
University of NebraskaTerminatedDiastolic Heart FailureUnited States
-
Arizona State UniversityMayo Clinic; University of AlbertaCompleted
-
University of PennsylvaniaCompletedHeart Failure | Diastolic Heart FailureUnited States
-
Chang Gung Memorial HospitalCompleted
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); PfizerCompleted
-
St Vincent's University Hospital, IrelandCompletedThe Effect of Eplerenone and Atorvastatin on Markers of Collagen Turnover in Diastolic Heart FailureDiastolic Heart FailureIreland
-
Synvista Therapeutics, IncTerminatedDiastolic Heart FailureUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States